XML 72 R63.htm IDEA: XBRL DOCUMENT v3.20.1
License and Other Agreements - BMS Agreement and Amendment (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Feb. 27, 2020
USD ($)
Mar. 31, 2018
USD ($)
Jul. 31, 2016
USD ($)
product
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
License and other agreements            
Required milestone payments capitalized to intangible asset         $ 41,500  
Research and development         56,070 $ 41,003
BMS Agreement            
License and other agreements            
Upfront payment under the BMS Amendment   $ 50,000        
BMS Agreement | Collaborative arrangement            
License and other agreements            
Payment required due to achievement of milestone $ 40,000          
Required milestone payments capitalized to intangible asset         40,000  
Milestone payments         20,000  
Payment to be paid on commencement of Phase 1 clinical trial     $ 2,000      
Payment to be paid on commencement of Phase 2 clinical trial     4,000      
Payment to be paid on commencement of Phase 3 clinical trial     6,000      
Payment required due to commencement of Phase 1 clinical trial 2,000          
Payment required due to commencement of Phase 2 clinical trial $ 4,000          
Research and development         $ 115 $ 0
BMS Agreement | Collaborative arrangement | Forecast            
License and other agreements            
Milestone payments       $ 20,000    
BMS Agreement | Collaborative arrangement | Maximum            
License and other agreements            
Milestone payment to be paid upon regulatory achievement     127,500      
Milestone payment to be paid for any product other than rimegepant     74,500      
Commercial milestone payment to be paid     $ 150,000      
BMS Agreement | Collaborative arrangement | Minimum            
License and other agreements            
Number of licensed products | product     1